Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics

Ligand Pharmaceuticals Incorporated (LGND): $81.56

-1.95 (-2.34%)

POWR Rating

Component Grades













Add LGND to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where LGND ranks best; there it ranks ahead of 65.16% of US stocks.
  • The strongest trend for LGND is in Growth, which has been heading down over the past 179 days.
  • LGND ranks lowest in Stability; there it ranks in the 18th percentile.

LGND Stock Summary

  • With a year-over-year growth in debt of -25.88%, Ligand Pharmaceuticals Inc's debt growth rate surpasses only 15.88% of about US stocks.
  • Over the past twelve months, LGND has reported earnings growth of 296.42%, putting it ahead of 92.84% of US stocks in our set.
  • As for revenue growth, note that LGND's revenue has grown 48.66% over the past 12 months; that beats the revenue growth of 80.91% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Ligand Pharmaceuticals Inc, a group of peers worth examining would be WATT, SITM, PI, MPWR, and PACB.
  • Visit LGND's SEC page to see the company's official filings. To visit the company's web site, go to

LGND Valuation Summary

  • LGND's EV/EBIT ratio is 46.3; this is 58.02% higher than that of the median Healthcare stock.
  • Over the past 243 months, LGND's price/sales ratio has gone down 0.9.
  • Over the past 243 months, LGND's price/sales ratio has gone down 0.9.

Below are key valuation metrics over time for LGND.

Stock Date P/S P/B P/E EV/EBIT
LGND 2021-08-31 8.8 2.8 46.1 46.3
LGND 2021-08-30 8.0 2.6 42.2 42.8
LGND 2021-08-27 7.6 2.4 39.8 40.7
LGND 2021-08-26 7.4 2.4 38.7 39.7
LGND 2021-08-25 7.5 2.4 39.5 40.4
LGND 2021-08-24 7.7 2.5 40.2 41.1

LGND Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 190.46%.
  • Its 2 year revenue growth rate is now at -34.54%.
  • Its 3 year net cashflow from operations growth rate is now at 277.8%.
LGND's revenue has moved up $148,310,000 over the prior 52 months.

The table below shows LGND's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 277.133 78.798 57.138
2021-09-30 274.65 51.693 68.315
2021-06-30 251.663 44.413 47.891
2021-03-31 208.408 48.418 39.252
2020-12-31 186.419 54.586 -2.985
2020-09-30 143.432 46.71 -16.111

LGND's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LGND has a Quality Grade of C, ranking ahead of 59.87% of graded US stocks.
  • LGND's asset turnover comes in at 0.195 -- ranking 202nd of 681 Pharmaceutical Products stocks.
  • NBIX, IRWD, and MNKD are the stocks whose asset turnover ratios are most correlated with LGND.

The table below shows LGND's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.195 0.774 0.067
2021-03-31 0.162 0.837 0.054
2020-12-31 0.148 0.837 0.016
2020-09-30 0.111 0.856 0.006
2020-06-30 0.092 0.862 0.002
2020-03-31 0.073 0.889 -0.026

LGND Price Target

For more insight on analysts targets of LGND, see our LGND price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $207.00 Average Broker Recommendation 1.43 (Moderate Buy)

LGND Stock Price Chart Interactive Chart >

Price chart for LGND

LGND Price/Volume Stats

Current price $81.56 52-week high $169.98
Prev. close $83.51 52-week low $77.80
Day low $79.30 Volume 132,806
Day high $82.67 Avg. volume 162,337
50-day MA $100.19 Dividend yield N/A
200-day MA $124.59 Market Cap 1.38B

Ligand Pharmaceuticals Incorporated (LGND) Company Bio

Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.

LGND Latest News Stream

Event/Time News Detail
Loading, please wait...

LGND Latest Social Stream

Loading social stream, please wait...

View Full LGND Social Stream

Latest LGND News From Around the Web

Below are the latest news stories about Ligand Pharmaceuticals Inc that investors may wish to consider to help them evaluate LGND as an investment opportunity.

Investors one-year losses grow to 37% as the stock sheds US$288m this past week

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...

Yahoo | February 24, 2022

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q4 2021 Results - Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q4 2021 Earnings Conference Call February 17, 2022 04:30 PM ET Company Participants Simon Latimer - Head of Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Chief Financial Officer Matt Foehr - Chief Operating Officer Conference Call Participants Joe Pantginis - H.C. Wainwright...

SA Transcripts on Seeking Alpha | February 18, 2022

Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22

Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline. The company plans to complete business separation in the first half of 2022.

Yahoo | February 18, 2022

Ligand Reports Fourth Quarter and Full Year 2021 Financial Results

EMERYVILLE, Calif., February 17, 2022--Ligand Reports Fourth Quarter and Full Year 2021 Financial Results

Yahoo | February 17, 2022

Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More

Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.

Yahoo | February 16, 2022

Read More 'LGND' Stories Here

LGND Price Returns

1-mo -16.15%
3-mo -14.14%
6-mo N/A
1-year -32.93%
3-year -28.06%
5-year -28.14%
YTD -47.20%
2021 55.31%
2020 -4.64%
2019 -23.15%
2018 -0.90%
2017 34.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7766 seconds.